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CAP2 has been suggested as a potential diagnostic biomarker for early hepatocellular carcinoma (HCC). However,
its prognostic significance in HCC remains unclear. Here, we show that CAP2 expression is much higher in HCC
tissues than that in paracarcinoma tissues, at both mRNA and protein levels. Data of immunohistochemistry (IHC)
revealed that CAP2 was markedly up-regulated in 77.3% of HCC cases. High CAP2 expression, defined by the
median score of IHC, was present in 53.3% of the patients. Kaplan-Meier analysis indicated that high CAP2
expression was associated with poor overall survival (P b .0001), disease-free survival (P = .013) and recurrence
probability (P = .004) in a training cohort of 312 HCC patients. The prognostic implication of CAP2 in HCC was
further confirmed in a validation cohort of 208 HCC patients and by stratified survival analysis. Multiple Cox
regression analysis indicated CAP2 as an independent predictor for overall survival (hazard ratio (HR) = 1.615, 95%
confidence interval: 1.345-1.938, P b .001). Collectively, we conclude that CAP2 is increased in HCC and is a novel
unfavorable biomarker for prognostic prediction for patients with this deadly disease.
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The 5-year survival for patients with hepatocellular carcinoma (HCC)
has been poorly improved worldwide last decades [1], despite the
advances in surgical management and the clinical implementation of
numerous therapeutic strategies. The mortality rate of HCC ranks the
second most common cause of cancer-related death in men and the
sixth in women [2]. The incidence of HCC has been increasing in
economically developed regions, including Japan, Western Europe
and the USA [3,4]. In view of the poor outcome of patients with
HCC, interests in developing novel strategies for HCC therapy have
been accumulating. Discovery of biological markers useful for HCC
prognostic prediction is one of the potential strategies to monitor the
progress of this deadly disease in clinical management.
Cyclase-associated protein (CAP), consisting of 474 to 551 amino
acid residues, is an evolutionary highly conserved protein between
yeast and mammals. It was firstly identified in the budding yeast
Saccharomyces cerevisiae [5]. CAP exerts functions towards the
activations of adenylyl cyclase and the mediating the dynamics of
actin polymerization by binding to G-actin [5,6]. Two homologs,CAP1 and CAP2, are present in higher eukaryotes. CAP1 and CAP2
share about 76% similarity in rat [7]. CAP2 is rarely present in a few
of tissues. It could co-localize with actin in skeletal muscle cells [8]. In
rat, CAP2 transcripts were found in testes, lung and kidney, but not
in liver and spleen [9]. During the development of mice embryos,
CAP2 was detectable throughout cardiogenesis [10]. Loss of CAP2
led to cardiomyopathy, according to the data that CAP2 depletion
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human cancers, CAP2 was differently expressed. For example, CAP2
was highly up-regulated in thyroid, kidney and bladder cancers. On
the contrary, CAP2 mRNA was found down-regulated in breast
fibroadenoma [12]. In HCC, CAP2 was demonstrated to be
overexpressed in several studies [8,13,14]. However, the relevant
prognostic implication of CAP2 has not been understood and
remains elusive.
In this study, the expression of CAP2 in HCC was examined. The
relationship between CAP2 expression and clinicopathological
features was investigated. The role of CAP2 in HCC prognosis was
assessed. Our results reveal that CAP2 is noticeably up-regulated in
HCC and significantly correlated with unfavorable prognosis.
Materials and Methods
Patients and Tissue Samples
HCC samples, along with the clinicopathological information,
were obtained from 520 HCC patients underwent surgical resection
at Sun Yat-sen University Cancer Center, Guangzhou, China,
between January 2000 and December 2010. This cohort consists of
470 (90.4%) male and 50 (9.6%) female. The mean age is 49,
ranging from 13.0 to 71.0. The mean follow-up time is 40.5 months.
Another 32 paired fresh resection HCC tissues and the corresponding
adjacent liver tissues were collected for quantitative real-time PCR
andWestern blot analysis. None of the patients had received adjuvant
therapies before surgery. The use of tissues for this study has been
approved by the Institute Research Medical Ethics Committee of Sun
Yat-sen University Cancer Center.
Immunohistochemistry (IHC)
Tissue microarray containing 520 HCC samples was constructed as
described in our previous study [15]. Formalin-fixed and paraffin-
embedded HCC sections were dewaxed in xylene and graded alcohols,
hydrated, and washed in PBS. After pretreatment in a microwave oven,
endogenous peroxidase was inhibited by 3% hydrogen peroxide in
methanol for 20 minutes, followed by avidin-biotin blocking using a
biotin-blocking kit (DAKO, Germany). Slides were then incubated
with CAP1 (Abcam, Cambridge,MA) and CAP2 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) overnight at 4°C, washed in PBS, and
incubated with biotinylated goat anti-rabbit/mouse antibodies (DAKO,
Germany). Slides were developed with DAB and counterstained with
hematoxylin.
IHC Evaluation
Semi-quantitative IHC detection was used to determine the CAP2
protein levels. For each case, 1000 cells were randomly selected and
scored independently by two pathologists (Dr. JP Yun and Dr. M Li).
The percentage of positively stained cells was scored as “0” (0%), “1”
(1% to 25%), “2” (26% to 50%), “3” (51% to 75%), “4” (76% to
100%). Intensity was scored as “0” (negative staining), “1” (weak
staining), “2” (moderate staining), and “3” (strong staining). The
percentage score was multiplied by the staining intensity score. The
median score of IHC staining was chosen as the cut-off value.
Quantitative Real-Time PCR (qRT-PCR) and Western Blot
qRT-PCR and western blot were performed as described in our
previous study [15]. Primers were designed as follows: CAP1,
forward: 5′- GCAGATTAATCAGGGGGAGAG-3′ and reverse: 5′-
TTCCTGATTTTCCACTCTCCAC-3′ ; CAP2, forward:5′-AGTACCAACAACCCCACGAG-3′ and reverse: 5′- TTCCAC
AATGCCCACCAC AT-3′; β-actin, forward: 5′-TGGCACCCAGC
ACAATGAA-3′ and reverse: 5′-CTAAGTCATAGTCCG
CCTAGAAGCA-3′.
Statistical Analysis
Statistical analyses were performed using the SPSS 16.0 software
(SPSS, Chicago, IL). Wilcoxon matched pairs test was used to
determine the significant difference of CAP2 expression. χ2 test was
performed to analyze the correlation between CAP2 expression and
clinicopathological parameters. Kaplan-Meier analysed (log-rank test)
was conducted for survival analysis and univariate analysis.
Independent analyses were performed according to the selected
population: overall population and different morphological and
pathological subgroups. Cox proportional hazards regression model
was used to identify the independent prognostic factors. Statistical
significance was set at P b .05.
Results
Expression of CAP2 in HCC Tissue Samples by qRT-PCR and
Western Blot
To determine the expression of CAP2 in HCC, 24 pairs of tumor
samples and the corresponding adjacent nontumorous samples were
collected. Results of qRT-PCR showed that CAP2 mRNA levels in
HCC were markedly increased in 87.5% (21/24) of the cases,
compared with the paracarcinoma tissues (Figure 1A). The
mRNA expression of CAP2 was found to be positively
connected with CAP1 mRNA expression (Figure 1B). Consis-
tently, the protein levels of CAP2 in 87.5% (14/16) of HCC
cases were noticeably up-regulated in HCC samples (Figure 1C). The
significant correlation of CAP2 and CAP1 protein expression was also
depicted (Figure 1D).
Expression of CAP2 in HCC Tissue Samples by IHC
To further confirm the overexpression of CAP2 in HCC, 520
paraffin-embedded HCC samples were collected to construct tissue
microarray. As shown by the results of IHC, positive staining of
CAP2 was presented in 94.8% (493/520) of tumorous tissues, but
only in 42.3% (220/520) of the nontumorous tissues. Furthermore,
77.3% (402/520) of patients with HCC expressed more CAP2
protein in tumorous tissue. CAP2 was mainly located in the
cytoplasm of tumor cells (Figure 2, A–C). The representative images
of CAP2 expression in nontumorous tissues were also recorded
(Figure 2,D–E). According to the IHC score, CAP2 expression in
HCC was remarkably higher than that in nontumorous tissues
(Figure 2F).
Association of CAP2 Expression and Clinical Outcome in HCC
To disclose the clinical value of CAP2 in HCC, the relationship
between CAP2 expression and the clinical variables of HCC patients
was analyzed. Based on the median score (7.33) of IHC staining of
CAP2, patients were divided into two groups defined as low CAP2
expression and high CAP2 expression. High CAP2 expression was
present in 53.3% of the patients. No significant associations were
depicted in CAP2 expression with the clinicopathological parameters
(Supplementary Table 1).
The prognostic implication of CAP2 in HCC was next determined.
Randomly, 520 patients with HCC were separated into two cohorts,
Figure 1. CAP2 expression is increased in HCC samples by qRT-PCR and Western blot. (A) mRNA levels of CAP2 were determined by
qRT-PCR in 24 paired freshHCC tissues. (B)Wilcoxonmatched paired test showed the relationship of CAP2 and CAP1 expression atmRNA
level. (C) Protein levels of CAP2 in tumorous samples (T) and corresponding adjacent nontumorous samples (N) were examined in 16 pairs
of HCC fresh tissues by western blot. (D) Correlation of protein expression normalized to GAPDH of CAP2 and CAP1 were calculated.
402 CAP2 indicates prognosis in HCC Fu et al. Translational Oncology Vol. 8, No. 5, 2015named training and validation cohorts. Kaplan-Meier analysis indicated
that, in the training cohort, HCC cases with highCAP2 expressionwere
usually accompanied with significantly worse prognosis, in terms ofFigure 2. CAP2 expression is increased in HCC samples by IHC.
immunoreactivities of CAP2 in HCC, as well as positive (D) and nega
panel: magnification ×100; Right panel: magnification ×400). F. W
score in HCC.overall survival (P b .001), disease-free survival (P = .013) and
recurrence-free survival (P = .004) (log-rank test; Figure 3, A–C ).
Consistently, low CAP2 expression was positively correlated withRepresentative images of strong (A), moderate (B) and weak (C)
tive (E) staining of CAP2 in normal liver tissues were shown (Left
ilcoxon matched paired test revealed a significant increase of IHC
Translational Oncology Vol. 8, No. 5, 2015 CAP2 indicates prognosis in HCC Fu et al. 403favorable overall survival (P b .001), disease-free survival (P = .011) and
recurrence-free survival (P = .006) in validation cohort (log-rank test;
Figure 3, D–F).
In line with the results of the individual cohort, patients with high
CAP2 were likely to have shorter overall survival (P b .001),
disease-free survival (P b .001) and recurrence-free survival (P b .001)
in the overall cohort (log-rank test; Figure 4). The prognostic
significance of CAP2 was further confirmed by stratified survival
analyses, showing that CAP2 expression was connected with overall
survival in small and large HCC (Figure 5, A–B), in unique and
multinodular HCC (Figure 5, C–D), regardless of the presence or
absence of microvascular invasion (Figure 5, E–F).Figure 3. High CAP2 expression is correlated with unfavorable pr
disclosed the significant differences in overall survival (A,D), dise
postoperative patients with high and low CAP2 expression in HCC trUnivariate and Multivariate Analyses of Prognostic Variables
in HCC
To evaluate the representative of our samples, univariate analyses
were performed. In training cohort, CAP2, as well as tumor size,
invonucrum, LNM, tumor differentiation and TNM, was responsible
for the survival of HCC patients. After adjusted for the prognostic
factors established in univariate analysis, a significant correlation of
high CAP2 expression with worse overall survival (hazard ratio
(HR) = 1.615, 95% confidence interval (95% CI): 1.271-2.051, P b
.001) was indicated by multiple Cox regression analysis (Supplemen-
tary Table 2). This was further confirmed in validation cohort (HR =
1.889, 95% CI: 1.403-2.544, P b .001) (Supplementary Table 3).ognosis in training and validation cohorts. Kaplan-Meier analysis
ase-free survival (B,E) and recurrence probability (C,F) between
aining (n = 312) and validation (n = 208) cohorts (log-rank test).
Figure 4. High CAP2 expression is correlated with unfavorable prognosis in overall cohort. Kaplan-Meier analysis disclosed the significant
differences in overall survival (A), disease-free survival (B) and recurrence probability (C) between postoperative patients with high and low
CAP2 expression in overall (n = 520) cohort (log-rank test).
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tumor size, tumor multiplicity, invonucrum, liver cirrhosis, serum
level of AFP, LNM, tumor differentiation, and TNM, was identified
as prognostic factor (Table 1). Multivariate analysis indicated CAP2
as an independent factor for overall survival (HR = 1.615, 95% CI:
1.345-1.938, P b .001) but not disease-free survival (Table 1 and data
not shown).
Discussion
In the recent years, searching for valuable biomarkers for HCC
diagnosis and prognostic prediction has been attracting more and
more interests. Numerous of factors, such as serum DKK1 [16] and
microRNA panel [17], have been proposed as potential diagnostic
biomarkers. On the other hand, abnormal expression of certain
proteins, e.g., cyclin F [15] and CXCL5, [18], was considered to be of
prognostic significance. In this study, we intended to determine the
prognostic value of CAP2 in a large cohort of primary HCC patients
who underwent curative surgery.
Current data suggest CAP2 is of diagnostic implication in early
HCC, which is defined as a vaguely nodular well-differentiated
tumor. Sakamoto et al. showed that CAP2 was expressed in 70% to
100% of early HCC to some extent, but only in 5% to 10%
precancerous lesions [19]. Our data present a marked increase of
CAP2 expression in HCC, compared with the nontumorous tissues.
Consistent with our study, Shibata and colleagues offered evidence
that CAP2 expression was increased in HCC, and that strong staining
of CAP2 was more frequently presented in progressed HCC,
compared to early HCC [13]. Similarly, Sakamoto et al. reported
that CAP2 expression was generally increased from early to advanced
stage of HCC [20]. However, in our study, the positive staining of
CAP2 was also depicted in 42.3% of nontumorous tissues, which is
much lower than that in HCC tissues. This may not meet the request
of specificity for clinical diagnosis. On the other hand, it is worth the
notice that CAP2 was somatically mutated in an early-stage primary
myelofibrosis patient [21]. Whether the altered expression of CAP2
in human cancer is due to its mutation is unknown and requires
further investigation. Undoubtedly, extensive studies should be done
to confirm whether CAP2 could be used as a practical biomarker for
the diagnosis of early HCC.
The prognostic value of CAP protein has been revealed in human
cancers. Yu et al. showed that CAP1 was overexpressed in breast
cancer and its knockdown inhibited cell proliferation and migration[22]. A later study showed that CAP1 overexpression in breast cancer
was associated with unfavorable prognosis [23]. Xie et al. showed that
CAP1 was up-regulated and predicted brain metastasis and poor
survival in non-small cell lung cancer [24]. Hua et al. reported that
CAP1 expression was induced, associated with Ki67 expression and
poor outcome in epithelial ovarian cancer [25]. In HCC, high
expression of CAP1 was correlated with unfavorable prognosis and
promoted tumor metastasis [26]. However, to date, the prognostic
implication of CAP2 in human cancer has not been understood. Our
data showed that CAP2 expression in a large cohort of 520 patients
with HCC was significantly associated with overall and disease-free
survival. Further statistical analyses indicated CAP2 as an indepen-
dent factor for prognostic prediction. Collectively, these data offer
some suggestions to HCC clinical management that which patients
should be under close surveillance for the tumor progression. Effendi
et al. reported that CAP2 expression in 105 HCC cases was
connected with tumor size, poor differentiation, portal vein invasion,
and intrahepatic metastasis [8]. Oppositely, our data showed that
CAP2 expression was not significantly correlated to the above
malignant parameter. The difference between the two studies
might be due to the cut-off value of IHC evaluation. In Effendi's
study, definition of high or low CAP2 expression was decided by
the positive control which was not provided, whereas in our study,
IHC score was based on the CAP2 immunoreactivity in tumor
cells. On the other hand, the sample size in our study (520 cases)
was much bigger than that in Effendi's study (105 cases). We
therefore considered our data was representative. Although our
study could not provide information for the biological function of
CAP2 in HCC development, literature showing that CAP2 is
continually expressed throughout the development of cardiogenesis
of mice embryos [10], and that CAP2 depletion resulted in
delayed scratch closure probably due to the function of CAP2 on
actin cytoskeleton [12], indicates that CAP2 might exert activities
during cell differentiation and migration. The role of CAP2 in
HCC, however, calls for further studies.
In summary, our data demonstrated that CAP2 expression was
noticeably increased in HCC tissues, compared with the nontumor-
ous tissues. High CAP2 expression was significantly correlated with
poor overall and disease-free survival. The prognostic implication was
also valid in several subgroups of HCC patients. Our study therefore
suggests CAP2 as a promising biomarker for prognosis of patients
with HCC.
Figure 5. CAP2 expression is associated with overall survival in subgroups of HCC patients. Stratified survival analyses showed that CAP2
expression was connected with overall survival in small and large HCC (A,B), in unique and multinodular HCC (C,D), regardless of the
presence or absence of microvascular invasion (E,F) (log-rank test).
Table 1. Univariate and Multivariate Analysis of Clinicopathological and Cap2 for Overall Survival in Overall Cohort (n = 520)
Variables Univariate Analysis Multivariate Analysis
HR (95% CI) P value HR (95% CI) P value
Age (b49 vs ≥49 years) 0.868(0.728-1.035) .114
Gender (female vs male) 1.021(0.758-1.376) .891
HBV (positive vs negative) 1.092(0.857-1.391) .478
Tumor size (b5 vs ≥5 cm) 1.420(1.148-1.757) .001
Tumor multiplicity (single vs multiple) 1.199(1.000-1.436) .049 0.800(0.640-1.000) .049
Invonucrum (absent vs present) 1.199(1.000-1.436) .000 0.800(0.666-0.960) .017
Liver cirrhosis (yes vs no) 0.744(0.588-0.941) .013 0.866(0.679-1.104) .244
AFP (b20 vs ≥20 ng/mL) 1.407(1.145-1.728) .001 1.174(0.948-1.455) .142
LNM (Yes vs no) 1.568(1.100-2.235) .013 1.338(0.931-1.921) .115
Tumor differentiation 1.879(1.394-2.531) .000 1.446(1.059-1.974) .020
TNM (I vs II-IV) 1.740(1.444-2.095) .000 1.765(1.398-2.229) .000
Cap2 expression (low vs high) 1.693(1.412-2.030) .000 1.615(1.345-1.938) .000
HR, hazard ratio; CI, confident interval; LNM, lymph node metastasis.
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